Develops and manufactures vaccines for infectious diseases. Commercializes vaccines for smallpox and monkeypox under the names IMVAMUNE, IMVANEX, and JYNNEOS. Now — the numbers.
This is an established company with proven profits.
Average growth of 33% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $496.9M would still be left in the vault — a solid cushion for hard times.
The market pays 11.8× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 45% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 22% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 33% a year on average.
There is $517.2M in the vault; even if every debt were paid off, $496.9M would remain.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.